07:00 , Oct 2, 1995 |  BC Week In Review  |  Company News

Avid Therapeutics, Emory University deal

The parties executed a previously announced licensing agreement under which Avid receives exclusive worldwide rights to antiviral compounds called polyoxometalates (see BioCentury Nov. 14, 1994). Avid Therapeutics Inc.   Emory University   Business: Infectious diseases...
07:00 , Apr 17, 1995 |  BC Week In Review  |  Company News

Avid Therapeutics, Terrapin deal

Avid (Philadelphia) and Terrapin (South San Francisco) will collaborate to discover drugs to treat hepatitis B virus (HBV). Avid will combine its rapid HBV assays with Terrapin's TRAP technology, which classifies compounds according to molecular...
08:00 , Nov 14, 1994 |  BC Week In Review  |  Company News

Avid Therapeutics deal

Avid (Philadelphia) received exclusive rights from Emory University to develop polyoxometalates to treat respiratory syncytial virus (RSV) and influenza. Avid said that although the compounds have a high molecular weight, some of them have demonstrated...
07:00 , Oct 10, 1994 |  BC Week In Review  |  Clinical News

Avid Therapeutics regulatory update

The Philadelphia company received two U.S. Patents covering its technologies for discovering drugs targeted at hepatitis B and herpes. Patent No. 5,334,524, licensed by Avid from the Fox Chase Cancer Center, covers a composition of...
07:00 , Jul 11, 1994 |  BC Week In Review  |  Company News

Avid Therapeutics deal

Philadelphia-based Avid received an exclusive worldwide license to molecular targets involving the herpes family of viruses from ARCH Development Corp., the technology licensing affiliate of the University of Chicago. The licensed targets are the herpes...
08:00 , Mar 21, 1994 |  BC Week In Review  |  Clinical News

Avid Therapeutics regulatory update

Avid received notice of allowance for a U.S. patent covering hepadnavirus polymerases with DNA priming and reverse transcriptase activities. Avid holds an exclusive license under these claims from the Fox Chase Cancer Center. Hepatitis B...
08:00 , Mar 14, 1994 |  BC Week In Review  |  Company News

Avid Therapeutics deal

Avid (Philadelphia) obtained an option from Emory University for exclusive worldwide rights to license several hundred non-nucleoside compounds to be evaluated using Avid's hepatitis B and hepatitis C assays. Avid Therapeutics Inc.  ...
08:00 , Feb 28, 1994 |  BC Week In Review  |  Company News

Avid Therapeutics other research news

The National Cancer Institute (NCI) granted the Philadelphia company access to NCI's natural products repository. The repository will provide the company with a wide range of natural products that will be evaluated using Avid's hepatitis...
07:00 , Oct 4, 1993 |  BC Week In Review  |  Company News

Avid Therapeutics deal

Avid Therapeutics Inc.   Avid entered into its first corporate partnership, a deal with Warner-Lambert Co. to develop drugs to treat hepatitis B. The collaboration will combine Avid's technology for identifying small molecule drugs with...